Shameema Sikder, MD, details a session she presented with Roomasa Channa, MD, at EnVision Summit 2026.

“Chronic noninfectious uveitis treated with systemic IMT is associated with fewer ocular complications and better control of inflammation. The results suggest that systemic IMT may be a more reliable ...

Bonnie An Henderson, MD, founder of EnVision Summit, highlights how the annual conference integrates MD and OD tracks, practical subspecialty updates, and structured opportunities for connection ...

Leukemic ocular involvement arises from direct infiltration, hematologic derangements (anemia, thrombocytopenia, hyperviscosity), opportunistic infections, or drug toxicity, and may be the first ...

PDE6A-associated RP, a rare form of inherited retinal disease (IRD), is characterized by nyctalopia, visual field defects, and significant loss of visual acuity (VA). The disease primarily affects the ...

New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first ...

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential. One might ask why topical eye drop medications remain the mainstay of glaucoma therapy in the US and ...

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and ...

Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before ...

China’s National Medical Products Administration (NMPA) has granted regulatory approval for 2 next-generation ophthalmic ...

Collapsing physicians into an undifferentiated “provider” category can obscure differences in expertise and accountability, complicating informed patient navigation of multidisciplinary teams.

Kuldev Singh, MD, MPH, is professor of ophthalmology and chief of the glaucoma division in the Department of Ophthalmology at Stanford University School of Medicine in Palo Alto, California. Most ...